Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Curr Oncol. 2021 Feb 8;28(1):837-841. doi: 10.3390/curroncol28010081.
Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved outcomes, rare adverse events, such as invasive fungal infections, have been reported with the use of first-generation BTK inhibitors. Invasive fungal infections carry a high morbidity and mortality risk. There have been several case reports describing the association between aspergillosis and ibrutinib treatment, but none with acalabrutinib, to our knowledge. In this case report, we describe a patient with CLL who developed an intracranial infection while receiving acalabrutinib.
布鲁顿酪氨酸激酶（BTK）抑制剂已成为治疗未经治疗和先前治疗的慢性淋巴细胞白血病（CLL）患者的重要疗法。尽管治疗效果有所改善，但仍有罕见的不良反应报告，如侵袭性真菌感染，这与第一代 BTK 抑制剂的使用有关。侵袭性真菌感染具有很高的发病率和死亡率风险。据我们所知，已有几例病例报告描述了侵袭性曲霉病与伊布替尼治疗之间的关联，但尚无与阿卡替尼相关的报告。在本病例报告中，我们描述了一名接受阿卡替尼治疗的 CLL 患者发生颅内感染的情况。
